Insulin Stabilization Designs for Enhanced Therapeutic Efficacy and Accessibility.

Autor: Zhang Y; Division of Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Stanford University, Stanford, California 94305, United States., Austin MJ; Division of Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Stanford University, Stanford, California 94305, United States.; Department of Chemistry, Stanford University, Stanford, California 94305, United States., Chou DH; Division of Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Stanford University, Stanford, California 94305, United States.

Publikováno v: Accounts of chemical research [Acc Chem Res] 2024 Nov 19; Vol. 57 (22), pp. 3303-3315. Date of Electronic Publication: 2024 Oct 28.

Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.

Autor: Dembitz V; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Physiology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia., Lawson H; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; The Institute of Cancer Research, London, UK., Burt R; Division of Cell and Molecular Biology, Imperial College London, London, UK.; Francis Crick Institute, London, UK., Natani S; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Philippe C; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; INSERM U1242, University of Rennes, Rennes, France., James SC; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Atkinson S; Division of Cell and Molecular Biology, Imperial College London, London, UK.; Francis Crick Institute, London, UK., Durko J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Wang LM; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; The Institute of Cancer Research, London, UK., Campos J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; The Institute of Cancer Research, London, UK., Magee AMS; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Woodley K; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Austin MJ; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Rio-Machin A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain., Casado P; Centre for Cancer Genomics & Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK., Bewicke-Copley F; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Centre for Cancer Genomics & Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK., Rodriguez Blanco G; The University of Edinburgh MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Pereira-Martins D; Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Oudejans L; Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Boet E; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, LabEx Toucan, Toulouse, France.; Équipe labellisée Ligue Nationale Contre le Cancer 2023, Toulouse, France., von Kriegsheim A; The University of Edinburgh MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Schwaller J; University Children's Hospital and Department of Biomedicine (DBM), University of Basel, Basel, Switzerland., Finch AJ; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK., Patel B; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Sarry JE; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, LabEx Toucan, Toulouse, France.; Équipe labellisée Ligue Nationale Contre le Cancer 2023, Toulouse, France., Tamburini J; Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva and Swiss Cancer Center Leman, Geneva, Switzerland., Schuringa JJ; Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Hazlehurst L; Modulation Therapeutics, Morgantown, WV, USA., Copland Iii JA; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA., Yuneva M; Francis Crick Institute, London, UK., Peck B; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK., Cutillas P; Centre for Cancer Genomics & Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK., Fitzgibbon J; Centre for Cancer Genomics & Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK., Rouault-Pierre K; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Kranc K; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; The Institute of Cancer Research, London, UK., Gallipoli P; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. p.gallipoli@qmul.ac.uk.

Publikováno v: Leukemia [Leukemia] 2024 Nov; Vol. 38 (11), pp. 2395-2409. Date of Electronic Publication: 2024 Aug 26.

ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions.

Autor: Pannell JS; University of California, San Diego, San Diego, California. Electronic address: jpannell@health.ucsd.edu., Corey AS; Panel Chair, Atlanta VA Health Care System and Emory University, Atlanta, Georgia., Shih RY; Panel Vice Chair, Uniformed Services University, Bethesda, Maryland., Austin MJ; University of Virginia Health System, Charlottesville, Virginia., Chu S; University of Washington, Seattle, Washington; University of British Columbia, Vancouver, British Columbia, Canada., Davis MA; Yale University School of Medicine, New Haven, Connecticut; Committee on Emergency Radiology-GSER., Ducruet AF; Barrow Neurological Institute, Phoenix, Arizona, Neurosurgery expert., Hunt CH; Mayo Clinic, Rochester, Minnesota; Commission on Nuclear Medicine and Molecular Imaging., Ivanidze J; Weill Cornell Medical College, New York, New York., Kalnins A; University of Chicago, Chicago, Illinois., Lacy ME; Washington State University, Spokane, Washington; American College of Physicians., Lo BM; Sentara Norfolk General Hospital/Eastern Virginia Medical School, Norfolk, Virginia; American College of Emergency Physicians., Setzen G; Albany ENT & Allergy Services, Albany, New York; American Academy of Otolaryngology-Head and Neck Surgery., Shaines MD; Albert Einstein College of Medicine Montefiore Medical Center, Bronx, New York, Primary care physician., Soares BP; Stanford University School of Medicine, Stanford, California., Soderlund KA; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Naval Medical Center Portsmouth, Portsmouth, Virginia., Thaker AA; University of Colorado School of Medicine, Aurora, Colorado., Wang LL; University of Cincinnati Medical Center, Cincinnati, Ohio., Burns J; Specialty Chair, Montefiore Medical Center, Bronx, New York.

Publikováno v: Journal of the American College of Radiology : JACR [J Am Coll Radiol] 2024 Jun; Vol. 21 (6S), pp. S21-S64.

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.

Autor: Di Mambro A; School of Life and Health Sciences, University of Roehampton, London, UK., Arroyo-Berdugo Y; School of Life and Health Sciences, University of Roehampton, London, UK., Fioretti T; CEINGE Biotecnologie Avanzate, Via Gaetano Salvatore, Napoli, Italy., Randles M; Chester Centre for Leukaemia Research, Chester Medical School, University of Chester, Chester, UK., Cozzuto L; Centre Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Rajeeve V; Barts Cancer Institute, Queen Mary University of London, London, UK., Cevenini A; CEINGE Biotecnologie Avanzate, Via Gaetano Salvatore, Napoli, Italy.; Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy., Austin MJ; Barts Cancer Institute, Queen Mary University of London, London, UK., Esposito G; CEINGE Biotecnologie Avanzate, Via Gaetano Salvatore, Napoli, Italy.; Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy., Ponomarenko J; Centre Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.; University Pompeu Fabra (UPF), Barcelona, Spain., Lucas CM; Chester Centre for Leukaemia Research, Chester Medical School, University of Chester, Chester, UK., Cutillas P; Barts Cancer Institute, Queen Mary University of London, London, UK., Gribben J; Barts Cancer Institute, Queen Mary University of London, London, UK., Williams O; Great Ormond Street Institute of Child Health London, UCL, London, UK., Calle Y; School of Life and Health Sciences, University of Roehampton, London, UK., Patel B; Barts Cancer Institute, Queen Mary University of London, London, UK., Esposito MT; School of Life and Health Sciences, University of Roehampton, London, UK. mariateresa.esposito@surrey.ac.uk.; School of Biosciences, University of Surrey, Guildford, UK. mariateresa.esposito@surrey.ac.uk.

Publikováno v: Oncogene [Oncogene] 2023 Dec; Vol. 42 (50), pp. 3670-3683. Date of Electronic Publication: 2023 Oct 27.

Chemoselective, Oxidation-Induced Macrocyclization of Tyrosine-Containing Peptides.

Autor: Keyes ED; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Mifflin MC; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Austin MJ; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Alvey BJ; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Lovely LH; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Smith A; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Rose TE; 1200 Pharma LLC, 6100 Bristol Parkway, Culver City, California 90230, United States., Buck-Koehntop BA; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Motwani J; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States., Roberts AG; Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States.

Publikováno v: Journal of the American Chemical Society [J Am Chem Soc] 2023 May 10; Vol. 145 (18), pp. 10071-10081. Date of Electronic Publication: 2023 Apr 29.